Forty-five adults undergoing thoracotomy were randomized to receive placebo, tenoxicam 20 mg or tenoxicam 40 mg IV during chest wall closure. All patients received intraoperative fentanyl and intercostal blocks followed by morphine by patient-controlled analgesia. Patient numbers 13 to 45 also received thoracic epidural analgesia by continuous infusion of bupivacaine 0.125%, patient numbers 25 to 45 having fentanyl 2 µg/ml added to the epidural infusion. Efficacy parameters and adverse reactions were assessed over the first 24 hours postoperatively. On a 100 mm visual analogue scale, mean (SD) pain at rest (adjusted area under curve for hours 1 to 24) was 25.8 (12.5), 17.4 (14.8) and 16.5 (13.3) mm for groups receiving placebo, 20 mg and 40 mg tenoxicam, respectively (ANOVA: P< 0.05). There were no significant differences between study groups postoperatively in pain on coughing, opioid consumption, blood gas measurements, nausea, vomiting, sedation, blood loss, haemoglobin or serum creatinine. One patient in each tenoxicam group reported epigastric pain, rated moderate. These data support the inclusion of tenoxicam 20 mg IV in the management of pain at rest for patients undergoing thoracotomy, but do not show additional benefit for a higher dose.
Anaesthetists have strongly promoted the provision of effective perioperative analgesia in recent years, citing medical and humanitarian justifications for interventions to ensure very low pain scores, even after major surgery [1] [2] [3] . Non-steroidal antiinflammatory drugs (NSAIDs) have been widely adopted for perioperative analgesia, typically in combination with other methods of pain relief 1, 3, 4 . Tenoxicam is an NSAID well suited for this application because it can be administered once a day parenterally or enterally [5] [6] [7] . In a general sense, there is ample evidence for the analgesic efficacy of tenoxicam. However, efficacy demonstrated for an analgesic in one setting may not necessarily extend to another. Given that the use of NSAIDs may be associated with serious adverse effects, especially during the perioperative period 4, 8, 9 , it is important to ensure that clinical practice is supported by appropriate data.
We have identified only one previous study of tenoxicam after thoracotomy 6 . In this study (from our own unit), a modest reduction in opioid consumption compared with placebo was documented in patients who received tenoxicam 20 mg IV at the time of surgery. No other benefit was documented. Furthermore, no neural blockade of any sort was used (which would be unusual today), and pain scores, measured only at rest, were high by contemporary standards.
Therefore, we aimed to re-examine the benefit of tenoxicam in patients undergoing thoracotomy, in the context of a more aggressive approach to postthoracotomy analgesia, with assessment of pain on coughing as well as at rest, and with inclusion of a larger dose of tenoxicam. A further aim of the study was to ensure, so far as possible, that pain scores overall were acceptably low (i.e. in keeping with those in more recent reports 1 ).
MATERIALS AND METHODS
Approval from the regional ethics committee and written informed consent from all patients were obtained. Fifteen patients were recruited into each of three groups, to provide statistical power of 80%, assuming a single factor design with three groups, P<0.05, SD=24 mm 6 and difference between groups >15 mm on a 100 mm visual analogue scale (VAS) 10 .
Patients were included in the study if they were ASA category 1, 2 or 3, were undergoing lateral thoracotomy and lung resection for any indication, and were between the ages of 18 and 80 years. Exclusion criteria were: hypersensitivity to NSAIDs (including aspirin) or morphine; asthma; history of drug addiction, severe cardiac, renal (preoperative creatinine ≥0.2 mmol/l) or hepatic disease, peptic ulceration, gastrointestinal bleeding or any bleeding disorder; pregnancy; presence of any neurological disease likely to interfere with pain perception; concurrent use of another experimental agent; or the use of NSAIDs, opioids, diuretics or angiotensin converting enzyme inhibitors in the 24 hours preceding surgery. Patients were retained in the study if a decision not to proceed with surgery was made after the chest had been opened.
Patients were assigned randomly, in blocks of six, stratified for surgeon, to receive placebo (T 0), tenoxicam 20 mg (T 20 ) or tenoxicam 40 mg (T 40 ) IV during chest wall closure, from ampoules that were sequentially numbered but otherwise indistinguishable. The study was double-blind with no access to the codes, other than by a formal contingency protocol, until all data had been entered into a computerized database and verified against a subset re-entered by a second person. All patients were included for the purpose of reporting side-effects. All patients except those excluded in accordance with the contingency protocol before the final code break were included in the efficacy analysis. To better ensure adequate analgesia for participating patients, reviews of pain scores without code break were planned after 12 and 24 patients had been recruited (two and four blocks of the randomization sequence). At these points the background analgesic regimen was revised (see below), but no change was permitted to any aspect of the protocol related to the administration or assessment of the study medication. No interim analysis of the results was undertaken.
Patients were premedicated with lorazepam 1 to 3 mg, famotidine 20 to 40 mg and metoclopramide 5 to 10 mg. Anaesthesia was induced with thiopentone, and maintained with isoflurane and nitrous oxide in oxygen. Vecuronium was used to provide muscle relaxation. A double-lumen endotracheal tube was used. All patients received cephradine, 1 g IV on induction, and at six hourly intervals for 24 hours postoperatively. Intraoperative analgesia was provided with fentanyl, up to 10 µg/kg at induction and thereafter up to 1 µg/kg up to every 30 minutes at the discretion of the anaesthetist. Before chest closure, the surgeon blocked the intercostal nerves for two dermatomes above and below the incision using bupivacaine 0.5%, 2 ml per nerve. Once consciousness had been regained, all patients were given a 5 mg loading dose of morphine. Additional doses of 2.5 mg were given to achieve adequate analgesia. Thereafter morphine was provided via a patient-controlled analgesia (PCA) system programmed to deliver a 1 mg bolus with a five-minute lockout and no pre-set limits. At the first planned review of the pain scores it was thought that analgesia overall could be improved, particularly on coughing (see Results and Figure 3 ). Therefore, a decision was made to modify the regimen used for background analgesia. Patient numbers 1 to 12 (group A) had received no thoracic epidural analgesia (TEA), so it was decided to incorporate TEA into the regimen. Consequently, in patient numbers 13 to 45 (groups B and C) a 16 gauge catheter was inserted into the epidural space at the mid-thoracic level either before or after induction of anaesthesia according to the usual practice of each anaesthetist. Before the start of surgery, a test dose of 2 ml of bupivacaine 0.5% with adrenaline 1:100,000 was given, followed five minutes later by a bolus dose of 5 to 10 ml of bupivacaine 0.5%. Additional 5 to 10 ml doses of 0.5% bupivacaine were given throughout the case at the discretion of the anaesthetist. Postoperatively, patient numbers 13 to 24 (group B) received an infusion of plain bupivacaine 0.125%. At the second review of pain scores (after patient 24) it was apparent that no improvement in analgesia had been achieved (see Results and Figure 3 ) and therefore it was decided to modify the background analgesic regimen again. Thus in patient numbers 25 to 45 (group C) fentanyl 2 µg/ml was added to the infusion of bupivacaine. All epidural infusions were started in recovery at 5 to 10 ml/hour and continued at a rate sufficient to provide a demonstrable block to cold sensation over dermatomes T 4 -T 10 . Patient monitoring was in accordance with the guidelines of the Australian and New Zealand College of Anaesthetists 11 . In addition, blood pressure was measured directly by means of a radial artery catheter, which was retained for six hours postoperatively, with the patients supervised in the recovery room for this purpose.
The primary outcome variables were pain at rest and pain on coughing, assessed as "present pain" using a 100 mm unmarked VAS with the anchors "no pain" and "severe pain". These data were recorded preoperatively (the night before surgery), and at 1, 2, 4, 6, 8, 12 and 24 hours postoperatively. Secondary outcome variables included the 24-hour cumulative postoperative morphine consumption, and the results of arterial blood gas analysis carried out on insertion of the arterial line and at 1, 2, 4 and 6 hours postoperatively. Pulse oximetry was recorded at 8, 12 and 24 hours. In addition, arterial haemoglobin oxygen saturations below 90% on pulse oximetry at any time during the first 24 hours after surgery were noted. Data were also collected in relation to nausea (graded by the patient on a four-point scale as "none", "mild", "moderate" or "severe"), vomiting (indicated by the patient as "yes" or "no"), and sedation (assessed by the research nurse on a three-point scale as "fully awake", "rousable" or "unrousable"). Postoperative blood loss was recorded as the amount drained during the first 24 hours after chest closure. Before surgery, and on the fifth postoperative day, haemoglobin, urea and creatinine concentrations were measured. Any blood transfused during the surgery or first five postoperative days was recorded. On day five, patients were asked to rate the experience of taking part in the study as "very positive", "positive", "neutral", "negative" or "very negative". Details of all adverse events were recorded. Each such event was allocated a severity rating jointly by two investigators, according to a standard protocol developed by Roche Products, and a judgement was made as to whether it should be attributed to the study medication. Study data collection was subject to formal independent audit by Roche Products (New Zealand) Ltd.
The area under the curve of the pain VAS was calculated for the 23-hour period from hour 1 to hour 24, and then divided by 23 (hours) to give a number between 0 and 100 mm (AUC23), comparable with (but not exactly equal to) an average pain score, for rest pain (adjusted REST AUC23 ) and cough pain (adjusted COUGH AUC23 ). Sedation and nausea scores for the study period were summed to give a single result for each patient.
Statistical analysis was performed using Systat 7.0 for Windows (SPSS Inc., Chicago, IL, U.S.A.). Where relevant, plots of the data were used to ensure that parametric statistical techniques were justifiable. The main analyses were with one-way analysis of variance (ANOVA), with covariates as indicated. For each variable, the planned contrasts (placebo vs combined tenoxicam groups and T 20 vs T 40 ) were calculated if the main effect was significant (specified as P 0.05). P values pertain to two-tailed tests, and are reported without correction. Unless otherwise indicated, results are reported as mean (SD).
RESULTS
We screened 104 patients to recruit 45 (Table 1) . Four patients were excluded from the efficacy analysis because their codes were broken during the study period. These included one patient in group T 0 because he returned to theatre for bleeding, one patient from group T 20 because he was given oral morphine elixir, one patient from group T 40 because he required postoperative ventilation, and a second patient from group T40 because he received naloxone.
The study groups were similar in respect of weight, gender, ASA status, baseline pain scores, ribresections or fractures, the side of surgery, the duration of surgery, and the use of intraoperative fentanyl ( Table 2) , but age was distributed unevenly (ANOVA: P=0.05). All patients underwent a lateral thoracotomy with an incision between fourth and seventh ribs. The indication for surgery was lung cancer in all but five patients. Four of these had infective indications (aspergillosis in two, tuberculosis in one and bronchiectasis in one) and the fifth had an oesophageal cyst.
There was a significant difference between the three study groups in pain at rest but not in pain on coughing (two-way ANOVA for study group and epidural regimen with age as a covariate: P=0.048 for adjusted REST AUC23 and P=0.79 for adjusted COUGH AUC23 ; Table 3 and Figures 1 and 2 ). There was a significant advantage in rest pain for the combined tenoxicam groups compared with the placebo group (t test: P=0.046), the scores being 17.0 There was no significant interaction between epidural and study groups.
There was a significant difference between the epidural regimens in pain on coughing (two-way ANOVA for study group and epidural regimen with age as a covariate: P=0.023), the scores for groups A, B and C being 47.0 (15.9) mm, 48.2 (19.9) mm and 29.8 (18.0) mm, respectively, for adjusted COUGH AUC23 . From inspection, this was clearly attributable to the lower scores in group C (Figure 3 ). There was no difference between epidural regimens for rest pain, the corresponding scores being 23.0 (13.6) mm, 21.2 (15.6) mm and 17.8 (13.3) mm for adjusted REST AUC23 (Figure 3 ). There was no significant difference between study groups or between epidural groups for cumulative morphine consumption over 24 hours (two-way ANOVA for study group and epidural regimen with age as a covariate).
In the first 24 hours after surgery, six (of 294) recordings of arterial haemoglobin oxygen saturation were below 90%, four in the tenoxicam groups and two in the placebo group. There was no significant difference between study groups for P a CO 2 , P a O 2 , and acid base status (repeated measures ANOVA), or for blood loss in the first 24 hours after surgery (ANOVA). Blood was transfused in eight patients, distributed between the three groups. Mean (SD) haemoglobin concentration for the three groups combined decreased from 133 (15) g.l -1 preoperatively to 115 (18) g.l -1 at day five postoperatively (paired t test: P<0.001), but there was no significant difference between groups (repeated measures ANOVA). Creatinine concentrations showed no significant change over time and no difference between groups 163 TENOXICAM AFTER THORACOTOMY (repeated measures ANOVA). The greatest individual increase (0.07 mmol.l -1 ) was in a patient who received placebo. Other than pain, nausea or vomiting, one adverse event was reported by each of six patients. These consisted of: one patient in each of groups T 20 and T 40 who reported epigastric pain, lasting one day each, rated as moderate, and judged as probably related to the study medication in both cases; and the four patients noted previously who were withdrawn from the efficacy analysis because of code break. Only the patient withdrawn after receiving naloxone experienced sedation severe enough to require intervention. There were no significant differences between the summed sedation or nausea scores for each group (Kruskal-Wallis). Six, three and two patients vomited in the T 0 , T 20 and T 40 groups respectively. No patient died and no adverse event persisted more than two days.
Twenty-three patients (56%) rated the experience of taking part in the study as "positive", 17 (41%) as "neutral", one (2%) as "negative" and none as "very positive" or "very negative", with no significant difference between study groups.
DISCUSSION
Patients who received tenoxicam, in the presence of an aggressive postoperative analgesic regimen, experienced significantly less pain at rest, but not on coughing, than those who received placebo. Differences between 20 mg and 40 mg doses of tenoxicam were not significant. No benefit was seen for tenoxicam in terms of cumulative morphine consumption, P a CO 2 , P a O 2 or acid-base status. No differences between groups were observed for any side-effect.
Epidural analgesia significantly reduced pain on coughing, but only with the inclusion of fentanyl. However, it should be noted that this study was a prospective, double-blind randomization of patients to three tenoxicam groups (T 0 , T 20 and T 40 ) and that it was not designed to examine the efficacy of the different regimens of epidural analgesia used in our patients. The data for the epidural regimens are important primarily in relation to the planned reviews of pain scores and the consequent decisions to change the analgesic regimen. These reviews and changes represented an iterative process of quality control, to ensure that participating patients received adequate analgesia. The particular attention paid to block randomization will have minimized the impact of the adjustments, and as an additional safeguard the epidural group was included in the primary analyses to allow for any confounding influence on the results. There was no plan to test a particular hypothesis with respect to epidurals. Indeed, had overall pain scores been acceptable in group A (the first 12 patients), no changes would have been made to the analgesic regimen.
This approach to the provision of background analgesia had disadvantages. The benefit of any analgesic is most easily demonstrated in the presence of at least moderate pain 12 , and the excellent pain scores achieved in group C, even in patients receiving placebo, left little room for improvement. However, this difficulty is central to the question addressed by our study. The analgesic properties of tenoxicam per se have been demonstrated previously. The question we wished to address was whether the addition of this NSAID (a member of a group of drugs with potentially hazardous side-effects) to an already effective analgesic regimen would provide any additional advantage to patients after thoracotomy. Arguably, we should have adopted the third, most effective analgesic regimen from the outset. However, at the time the study was designed we hoped that the combination of intercostal blocks and PCA morphine would provide very good analgesia. In the event, at each of the two reviews, we thought that pain scores on coughing left room for improvement, and that additional analgesic measures were warranted. Endorsement of these decisions is to be found in the improved pain scores on coughing seen in group C, compared with groups A and B. Patients are not all managed in the same way in clinical practice, and the risk that our findings would not apply in less tightly controlled circumstances would also have been reduced by our approach. Given the excellent analgesia achievable by modern regimens 1 , we suggest that all analgesic studies should include some form of audit to ensure that participating patients are experiencing satisfactory levels of pain relief. Similarly, some check on the overall experience of participants in the study is appropriate, and we note that only one of our patients reported this experience as negative, while the majority rated it as positive.
Other factors might have confounded our results. The four patients excluded from the analysis because of incomplete data sets and/or code breaks were reasonably well distributed amongst groups. Tenoxicam recipients were significantly younger than those who received placebo, but we allowed for this by including age as a covariate in the analyses of variance of the pain scores and morphine consumption. The study size was chosen to have adequate power for the ANOVA of each of the two primary outcome variables, not necessarily for a post hoc analysis of differences between tenoxicam groups. Therefore, on the basis of this study, it is not possible to exclude a benefit for the larger dose of tenoxicam, but our data suggest that any such additional advantage would be less than the difference between either of the doses of tenoxicam and placebo.
The adjustment to the area-under-the-curve measurements (i.e. division by the number of hours) was undertaken to provide an intuitively interpretable measure (in mm), comparable with an average pain score, without influencing the statistical analysis. It was not appropriate to calculate averages directly from the pain scores because of the varying periods between estimates of pain.
A number of studies have compared the efficacy of NSAIDs with that of placebo in the management of pain following thoracotomy, and most have shown either improved analgesia, or reduced opioid consumption, or both 6, [13] [14] [15] [16] [17] . Benefit from NSAIDs has been less readily demonstrated in the presence of TEA with combined local anaesthetic and opioid. Bigler and colleagues were unable to show any benefit for rectal piroxicam when added to an epidural infusion of bupivacaine and morphine 18 , whereas Singh and co-workers found a similar analgesic effect for either epidural bupivacaine or intravenous ketorolac when added to an infusion of epidural hydromorphone for post-thoracotomy pain 19 . Two studies have demonstrated improvements in respiratory mechanics with indomethacin, in comparison with placebo 16, 17 . We did not investigate respiratory mechanics, but our data showed no benefit in blood gas recordings for six hours, or pulse oximetry recordings at any time during the study period. The findings of the one previous study involving tenoxicam after thoracotomy differed from ours, by showing a reduction in PCA papaveretum consumption over 12 hours, but no difference in pain scores 6 . One explanation for this difference may be found in the analgesic regimens. In the previous study, PCA papaveretum was the main analgesic, whereas in the present study a multimodal approach to analgesia was used.
Our data give no cause for concern over the safety or tolerability of tenoxicam as used in this study, but a formal assessment of safety would require a much greater number of patients 4, 5, 20 .
In conclusion, we have demonstrated a modest gain in postoperative analgesia for a single IV dose of tenoxicam in the setting of thoracic surgery, but only in respect of pain at rest and with no advantage for a dose of 40 mg over one of 20 mg. In a recent survey of 27 Australian thoracic surgical units, NSAIDs were "always/often" used in only five hospitals, whereas TEA was "always/often" utilized in 16 institutions 21 . Outcome after thoracic surgery is more likely to be influenced by pain on coughing than by pain at rest (because active coughing is important for the preservation of lung function), so our results provide some support for this pattern of practice, particularly given the number of patients undergoing thoracotomy who may have a contraindication to NSAIDs. Nevertheless, pain at rest may be troublesome after thoracotomy, and may possibly contribute to chronic post thoracotomy pain 22 . The risk of a single 20 mg dose of tenoxicam is very low 4 , so it may equally be thought that our data justify its use in patients undergoing thoracotomy, either routinely, or at least in those individuals for whom postoperative pain at rest is expected to be problematic. Future work should continue to refine our understanding of the role of particular NSAIDs in specific clinical settings, including newer agents that selectively inhibit the inducible form of cyclo-oxygenase 23, 24 and that may be suitable for a wider range of patients.
